Identification

Name
Mevastatin
Accession Number
DB06693
Type
Small Molecule
Groups
Experimental
Description

Mevastatin or compactin is a cholesterol-lowering agent isolated from Penicillium citinium. It was the first discovered agent belonging to the class of cholesterol-lowering medications known as statins. During a search for antibiotic compounds produced by fungi in 1971, Akira Endo at Sankyo Co. (Japan) discovered a class of compounds that appeared to lower plasma cholesterol levels. Two years later, the research group isolated a compound structurally similar to hydroxymethylglutarate (HMG) that inhibited the incorporation of acetate. The compound was proposed to bind to the reductase enzyme and was named compactin. Mevastatin is a competitive inhibitor of HMG-Coenzyme A (HMG-CoA) reductase with a binding affinity 10,000 times greater than the HMG-CoA substrate itself. Mevastatin is a pro-drug that is activated by in vivo hydrolysis of the lactone ring. It has served as one of the lead compounds for the development of the synthetic compounds used today.

Structure
Thumb
Synonyms
  • Mevastatina
  • Mévastatine
  • mevastatinum
External IDs
Antibiotic ML 236B / CS 500 / ML 236 B / ML-236B
International/Other Brands
Compactin
Categories
UNII
1UQM1K0W9X
CAS number
73573-88-3
Weight
Average: 390.52
Monoisotopic: 390.240624195
Chemical Formula
C23H34O5
InChI Key
AJLFOPYRIVGYMJ-INTXDZFKSA-N
InChI
InChI=1S/C23H34O5/c1-4-14(2)23(26)28-20-7-5-6-16-9-8-15(3)19(22(16)20)11-10-18-12-17(24)13-21(25)27-18/h6,8-9,14-15,17-20,22,24H,4-5,7,10-13H2,1-3H3/t14-,15-,17+,18+,19-,20-,22-/m0/s1
IUPAC Name
(1S,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate
SMILES
[H][C@]12[C@H](CCC=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC

Pharmacology

Indication

Not used therapeutically due to its many side effects.

Pharmacodynamics

The primary cause of cardiovascular disease is atherosclerotic plaque formation. Sustained elevations of cholesterol in the blood increase the risk of cardiovascular disease. Mevastatin lowers hepatic production of cholesterol by competitively inhibiting HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step in the cholesterol biosynthesis pathway via the mevalonic acid pathway. Decreased hepatic cholesterol levels causes increased uptake of low density lipoprotein (LDL) cholesterol and reduces cholesterol levels in the circulation.

Mechanism of action

Mevastatin is structurally similar to the HMG, a substituent of the endogenous substrate of HMG-CoA reductase. Mevastatin is a prodrug that is activated in vivo via hydrolysis of the lactone ring. The hydrolyzed lactone ring mimics the tetrahedral intermediate produced by the reductase allowing the agent to bind with 10,000 times greater affinity than its natural substrate. The bicyclic portion of mevastatin binds to the coenzyme A portion of the active site.

TargetActionsOrganism
A3-hydroxy-3-methylglutaryl-coenzyme A reductase
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Side effects include those of other statins, such as myalgias, abdominal pain, nausea. It also has a higher chance of giving more severe side effects related to myotoxicity (myopathy, myositis, rhabdomyolysis), and hepatotoxicity, than other statins. Due to these major side effects and their enhanced rate of occurance, Mevastatin is not given therapeutically.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
6-Deoxyerythronolide BThe risk or severity of rhabdomyolysis can be increased when 6-Deoxyerythronolide B is combined with Mevastatin.Experimental
AcetaminophenThe serum concentration of Mevastatin can be increased when it is combined with Acetaminophen.Approved
AcetazolamideThe serum concentration of Mevastatin can be increased when it is combined with Acetazolamide.Approved, Vet Approved
Acetyl sulfisoxazoleThe serum concentration of Mevastatin can be increased when it is combined with Acetyl sulfisoxazole.Approved, Vet Approved
AcipimoxAcipimox may increase the myopathic rhabdomyolysis activities of Mevastatin.Approved, Investigational
AgmatineThe therapeutic efficacy of Mevastatin can be increased when used in combination with Agmatine.Experimental, Investigational
AldesleukinThe serum concentration of Mevastatin can be increased when it is combined with Aldesleukin.Approved
AlmasilateThe serum concentration of Mevastatin can be decreased when it is combined with Almasilate.Approved, Experimental
AloglutamolThe serum concentration of Mevastatin can be decreased when it is combined with Aloglutamol.Approved
AlprazolamThe serum concentration of Mevastatin can be increased when it is combined with Alprazolam.Approved, Illicit, Investigational
AluminiumThe serum concentration of Mevastatin can be decreased when it is combined with Aluminium.Approved, Investigational
Aluminium acetoacetateThe serum concentration of Mevastatin can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Mevastatin can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe serum concentration of Mevastatin can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
AmbroxolThe serum concentration of Mevastatin can be increased when it is combined with Ambroxol.Approved, Investigational
AmiodaroneThe serum concentration of Mevastatin can be decreased when it is combined with Amiodarone.Approved, Investigational
AmlodipineThe serum concentration of Mevastatin can be increased when it is combined with Amlodipine.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Mevastatin.Approved, Investigational
AmprenavirThe serum concentration of Mevastatin can be increased when it is combined with Amprenavir.Approved, Investigational
AmrinoneThe therapeutic efficacy of Mevastatin can be increased when used in combination with Amrinone.Approved
AnastrozoleThe serum concentration of Mevastatin can be increased when it is combined with Anastrozole.Approved, Investigational
AntipyrineThe serum concentration of Mevastatin can be increased when it is combined with Antipyrine.Approved, Investigational
AprepitantThe serum concentration of Mevastatin can be increased when it is combined with Aprepitant.Approved, Investigational
AranidipineThe therapeutic efficacy of Mevastatin can be increased when used in combination with Aranidipine.Approved, Investigational
Arsenic trioxideThe serum concentration of Mevastatin can be increased when it is combined with Arsenic trioxide.Approved, Investigational
AstemizoleThe serum concentration of Mevastatin can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Mevastatin can be increased when it is combined with Asunaprevir.Approved, Investigational, Withdrawn
AtazanavirThe risk or severity of rhabdomyolysis can be increased when Atazanavir is combined with Mevastatin.Approved, Investigational
AtomoxetineThe serum concentration of Mevastatin can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Mevastatin can be increased when it is combined with Atorvastatin.Approved
AVE9633The risk or severity of rhabdomyolysis can be increased when AVE9633 is combined with Mevastatin.Investigational
AzelastineThe serum concentration of Mevastatin can be increased when it is combined with Azelastine.Approved
AzelnidipineThe therapeutic efficacy of Mevastatin can be increased when used in combination with Azelnidipine.Approved, Investigational
AzimilideThe therapeutic efficacy of Mevastatin can be increased when used in combination with Azimilide.Investigational
AzithromycinThe serum concentration of Mevastatin can be increased when it is combined with Azithromycin.Approved
BarnidipineThe therapeutic efficacy of Mevastatin can be increased when used in combination with Barnidipine.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Mevastatin.Investigational
BencyclaneThe therapeutic efficacy of Mevastatin can be increased when used in combination with Bencyclane.Experimental
BenidipineThe therapeutic efficacy of Mevastatin can be increased when used in combination with Benidipine.Approved, Investigational
BepridilThe therapeutic efficacy of Mevastatin can be increased when used in combination with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Mevastatin can be increased when it is combined with Betamethasone.Approved, Vet Approved
BezafibrateBezafibrate may increase the myopathic rhabdomyolysis activities of Mevastatin.Approved, Investigational
BicalutamideThe serum concentration of Mevastatin can be increased when it is combined with Bicalutamide.Approved
BifonazoleThe serum concentration of Mevastatin can be increased when it is combined with Bifonazole.Approved, Investigational
BioallethrinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Bioallethrin.Approved, Experimental
Bismuth subcitrate potassiumThe serum concentration of Mevastatin can be decreased when it is combined with Bismuth Subcitrate.Approved, Investigational
Bismuth subnitrateThe serum concentration of Mevastatin can be decreased when it is combined with Bismuth subnitrate.Approved
BoceprevirThe serum concentration of Mevastatin can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe serum concentration of Mevastatin can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe metabolism of Mevastatin can be increased when combined with Bosentan.Approved, Investigational
Brefeldin AThe risk or severity of rhabdomyolysis can be increased when Brefeldin A is combined with Mevastatin.Experimental
Brentuximab vedotinThe serum concentration of Mevastatin can be increased when it is combined with Brentuximab vedotin.Approved, Investigational
BromocriptineThe serum concentration of Mevastatin can be increased when it is combined with Bromocriptine.Approved, Investigational
Bryostatin 1The risk or severity of rhabdomyolysis can be increased when Bryostatin 1 is combined with Mevastatin.Investigational
BuprenorphineThe serum concentration of Mevastatin can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Mevastatin.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Mevastatin.Approved, Investigational
CabergolineThe serum concentration of Mevastatin can be increased when it is combined with Cabergoline.Approved
CaffeineThe serum concentration of Mevastatin can be increased when it is combined with Caffeine.Approved
Calcium CarbonateThe serum concentration of Mevastatin can be decreased when it is combined with Calcium Carbonate.Approved, Investigational
Calcium silicateThe serum concentration of Mevastatin can be decreased when it is combined with Calcium silicate.Experimental
CandicidinThe risk or severity of rhabdomyolysis can be increased when Candicidin is combined with Mevastatin.Withdrawn
CapsaicinThe serum concentration of Mevastatin can be increased when it is combined with Capsaicin.Approved
CarbomycinThe risk or severity of rhabdomyolysis can be increased when Carbomycin is combined with Mevastatin.Vet Approved
CarboxyamidotriazoleThe therapeutic efficacy of Mevastatin can be increased when used in combination with Carboxyamidotriazole.Investigational
CaroverineThe therapeutic efficacy of Mevastatin can be increased when used in combination with Caroverine.Experimental
CaspofunginThe serum concentration of Mevastatin can be increased when it is combined with Caspofungin.Approved
CeritinibThe serum concentration of Mevastatin can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Mevastatin can be increased when it is combined with Cerivastatin.Approved, Withdrawn
CethromycinThe risk or severity of rhabdomyolysis can be increased when Cethromycin is combined with Mevastatin.Investigational
ChloramphenicolThe serum concentration of Mevastatin can be increased when it is combined with Chloramphenicol.Approved, Vet Approved
ChlorzoxazoneThe serum concentration of Mevastatin can be increased when it is combined with Chlorzoxazone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Mevastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
CilnidipineThe therapeutic efficacy of Mevastatin can be increased when used in combination with Cilnidipine.Approved, Investigational
CilostazolThe serum concentration of Mevastatin can be increased when it is combined with Cilostazol.Approved, Investigational
CimetidineThe serum concentration of Mevastatin can be increased when it is combined with Cimetidine.Approved, Investigational
Cimicifuga racemosaThe serum concentration of Mevastatin can be increased when it is combined with Cimicifuga racemosa.Approved, Experimental
CinnarizineThe therapeutic efficacy of Mevastatin can be increased when used in combination with Cinnarizine.Approved, Investigational
CiprofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofibrate is combined with Mevastatin.Approved, Investigational
CiprofloxacinThe serum concentration of Mevastatin can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Mevastatin.Approved, Investigational, Withdrawn
ClarithromycinThe serum concentration of Mevastatin can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Mevastatin can be increased when it is combined with Clemastine.Approved, Investigational
ClevidipineThe therapeutic efficacy of Mevastatin can be increased when used in combination with Clevidipine.Approved, Investigational
ClindamycinThe serum concentration of Mevastatin can be increased when it is combined with Clindamycin.Approved, Vet Approved
ClofazimineThe serum concentration of Mevastatin can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Mevastatin can be increased when it is combined with Clomifene.Approved, Investigational
ClotiazepamThe serum concentration of Mevastatin can be increased when it is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe serum concentration of Mevastatin can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Mevastatin can be increased when it is combined with Clozapine.Approved
CobicistatThe serum concentration of Mevastatin can be increased when it is combined with Cobicistat.Approved
CocaineThe serum concentration of Mevastatin can be increased when it is combined with Cocaine.Approved, Illicit
ColchicineColchicine may increase the myopathic rhabdomyolysis activities of Mevastatin.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Mevastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Mevastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Coltuximab ravtansineThe risk or severity of rhabdomyolysis can be increased when Coltuximab ravtansine is combined with Mevastatin.Investigational
ConivaptanThe serum concentration of Mevastatin can be increased when it is combined with Conivaptan.Approved, Investigational
Cortisone acetateThe serum concentration of Mevastatin can be increased when it is combined with Cortisone acetate.Approved, Investigational
CrizotinibThe serum concentration of Mevastatin can be increased when it is combined with Crizotinib.Approved
CurcuminThe serum concentration of Mevastatin can be increased when it is combined with Curcumin.Approved, Investigational
CyclandelateThe therapeutic efficacy of Mevastatin can be increased when used in combination with Cyclandelate.Approved
CyclophosphamideThe serum concentration of Mevastatin can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Mevastatin.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Mevastatin can be increased when it is combined with Cyproterone acetate.Approved, Investigational
DaclatasvirThe serum concentration of Mevastatin can be increased when it is combined with Daclatasvir.Approved, Investigational
DalfopristinThe serum concentration of Mevastatin can be increased when it is combined with Dalfopristin.Approved
DanazolThe risk or severity of myopathy and rhabdomyolysis can be increased when Danazol is combined with Mevastatin.Approved
DaptomycinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Daptomycin.Approved, Investigational
DarodipineThe therapeutic efficacy of Mevastatin can be increased when used in combination with Darodipine.Experimental
DarunavirThe serum concentration of Mevastatin can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Mevastatin can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Mevastatin can be increased when it is combined with Daunorubicin.Approved
DelavirdineThe serum concentration of Mevastatin can be increased when it is combined with Delavirdine.Approved
DesipramineThe serum concentration of Mevastatin can be increased when it is combined with Desipramine.Approved, Investigational
DexamethasoneThe serum concentration of Mevastatin can be increased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextropropoxypheneThe serum concentration of Mevastatin can be increased when it is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DiazepamThe serum concentration of Mevastatin can be increased when it is combined with Diazepam.Approved, Illicit, Investigational, Vet Approved
DidanosineDidanosine can cause a decrease in the absorption of Mevastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DiethylstilbestrolThe serum concentration of Mevastatin can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DihydroergotamineThe serum concentration of Mevastatin can be increased when it is combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe serum concentration of Mevastatin can be increased when it is combined with Diltiazem.Approved, Investigational
Dimethyl sulfoxideThe serum concentration of Mevastatin can be increased when it is combined with Dimethyl sulfoxide.Approved, Vet Approved
DirithromycinThe risk or severity of rhabdomyolysis can be increased when Dirithromycin is combined with Mevastatin.Approved, Investigational
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Mevastatin.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Mevastatin.Approved, Investigational
DoramectinThe risk or severity of rhabdomyolysis can be increased when Doramectin is combined with Mevastatin.Vet Approved
DotarizineThe therapeutic efficacy of Mevastatin can be increased when used in combination with Dotarizine.Investigational
DoxorubicinThe serum concentration of Mevastatin can be increased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe serum concentration of Mevastatin can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe serum concentration of Mevastatin can be increased when it is combined with Dronedarone.Approved
EconazoleThe serum concentration of Mevastatin can be increased when it is combined with Econazole.Approved
EfavirenzThe serum concentration of Mevastatin can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe serum concentration of Mevastatin can be increased when it is combined with Efonidipine.Approved, Investigational
ElbasvirThe serum concentration of Mevastatin can be increased when it is combined with Elbasvir.Approved
EnasidenibThe serum concentration of Mevastatin can be increased when it is combined with Enasidenib.Approved, Investigational
EperisoneThe therapeutic efficacy of Mevastatin can be increased when used in combination with Eperisone.Approved, Investigational
EpinephrineThe serum concentration of Mevastatin can be increased when it is combined with Epinephrine.Approved, Vet Approved
EpofolateThe risk or severity of rhabdomyolysis can be increased when Epofolate is combined with Mevastatin.Investigational
Epothilone DThe risk or severity of rhabdomyolysis can be increased when Epothilone D is combined with Mevastatin.Experimental, Investigational
EprinomectinThe risk or severity of rhabdomyolysis can be increased when Eprinomectin is combined with Mevastatin.Vet Approved
ErgonovineThe serum concentration of Mevastatin can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Mevastatin can be increased when it is combined with Ergotamine.Approved
ErlotinibThe risk or severity of adverse effects can be increased when Erlotinib is combined with Mevastatin.Approved, Investigational
ErythromycinThe serum concentration of Mevastatin can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EthanolThe serum concentration of Mevastatin can be increased when it is combined with Ethanol.Approved
EthosuximideThe therapeutic efficacy of Mevastatin can be increased when used in combination with Ethosuximide.Approved
EtoposideThe serum concentration of Mevastatin can be increased when it is combined with Etoposide.Approved
EtoricoxibThe serum concentration of Mevastatin can be increased when it is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Mevastatin.Approved
EverolimusThe risk or severity of rhabdomyolysis can be increased when Everolimus is combined with Mevastatin.Approved
EzetimibeThe serum concentration of Mevastatin can be increased when it is combined with Ezetimibe.Approved
FelodipineThe serum concentration of Mevastatin can be increased when it is combined with Felodipine.Approved, Investigational
FendilineThe therapeutic efficacy of Mevastatin can be increased when used in combination with Fendiline.Withdrawn
FenofibrateThe risk or severity of myopathy and rhabdomyolysis can be increased when Fenofibrate is combined with Mevastatin.Approved
FentanylThe serum concentration of Mevastatin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
Fish oilThe therapeutic efficacy of Mevastatin can be increased when used in combination with Fish oil.Approved, Nutraceutical
FluconazoleThe risk or severity of adverse effects can be increased when Fluconazole is combined with Mevastatin.Approved, Investigational
FlunarizineThe therapeutic efficacy of Mevastatin can be increased when used in combination with Flunarizine.Approved
FluoxetineThe serum concentration of Mevastatin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlurithromycinThe risk or severity of rhabdomyolysis can be increased when Flurithromycin is combined with Mevastatin.Experimental
FluspirileneThe therapeutic efficacy of Mevastatin can be increased when used in combination with Fluspirilene.Approved, Investigational
Fluticasone propionateThe serum concentration of Mevastatin can be increased when it is combined with Fluticasone propionate.Approved
FluvastatinThe serum concentration of Mevastatin can be increased when it is combined with Fluvastatin.Approved
FluvoxamineThe serum concentration of Mevastatin can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Mevastatin can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Mevastatin can be increased when it is combined with Fosaprepitant.Approved
FosnetupitantThe serum concentration of Mevastatin can be increased when it is combined with Fosnetupitant.Approved
FosphenytoinThe serum concentration of Mevastatin can be decreased when it is combined with Fosphenytoin.Approved, Investigational
Fusidic AcidThe risk or severity of adverse effects can be increased when Fusidic Acid is combined with Mevastatin.Approved, Investigational
GabapentinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Gabapentin.Approved, Investigational
GallopamilThe therapeutic efficacy of Mevastatin can be increased when used in combination with Gallopamil.Investigational
GemfibrozilThe risk or severity of rhabdomyolysis, myoglobinuria, and elevated creatine kinase (CPK) can be increased when Gemfibrozil is combined with Mevastatin.Approved
GlyburideThe serum concentration of Mevastatin can be increased when it is combined with Glyburide.Approved
Glycerol PhenylbutyrateThe serum concentration of Mevastatin can be increased when it is combined with Glycerol Phenylbutyrate.Approved
GPI-1485The risk or severity of rhabdomyolysis can be increased when GPI-1485 is combined with Mevastatin.Investigational
HaloperidolThe serum concentration of Mevastatin can be increased when it is combined with Haloperidol.Approved
HistamineThe serum concentration of Mevastatin can be increased when it is combined with Histamine.Approved, Investigational
HydralazineThe serum concentration of Mevastatin can be increased when it is combined with Hydralazine.Approved
HydrocortisoneThe serum concentration of Mevastatin can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydrotalciteThe serum concentration of Mevastatin can be decreased when it is combined with Hydrotalcite.Approved, Experimental, Investigational
IdelalisibThe serum concentration of Mevastatin can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of Mevastatin can be increased when it is combined with Ifosfamide.Approved
IloperidoneThe serum concentration of Mevastatin can be increased when it is combined with Iloperidone.Approved
ImatinibThe serum concentration of Mevastatin can be increased when it is combined with Imatinib.Approved
IndinavirThe serum concentration of Mevastatin can be increased when it is combined with Indinavir.Approved
IndisulamThe serum concentration of Mevastatin can be increased when it is combined with Indisulam.Investigational
IrbesartanThe serum concentration of Mevastatin can be increased when it is combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Mevastatin can be increased when it is combined with Irinotecan.Approved, Investigational
IsavuconazoleThe serum concentration of Mevastatin can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Mevastatin can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoniazidThe serum concentration of Mevastatin can be increased when it is combined with Isoniazid.Approved, Investigational
IsradipineThe serum concentration of Mevastatin can be increased when it is combined with Isradipine.Approved, Investigational
ItraconazoleThe serum concentration of Mevastatin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Mevastatin can be increased when it is combined with Ivacaftor.Approved
IvermectinThe risk or severity of rhabdomyolysis can be increased when Ivermectin is combined with Mevastatin.Approved, Investigational, Vet Approved
IxabepiloneThe risk or severity of rhabdomyolysis can be increased when Ixabepilone is combined with Mevastatin.Approved, Investigational
JosamycinThe serum concentration of Mevastatin can be increased when it is combined with Josamycin.Approved, Investigational
KetazolamThe serum concentration of Mevastatin can be increased when it is combined with Ketazolam.Approved
KetoconazoleThe serum concentration of Mevastatin can be increased when it is combined with Ketoconazole.Approved, Investigational
KitasamycinThe risk or severity of rhabdomyolysis can be increased when Kitasamycin is combined with Mevastatin.Experimental
KOS-1584The risk or severity of rhabdomyolysis can be increased when KOS-1584 is combined with Mevastatin.Investigational
LacidipineThe therapeutic efficacy of Mevastatin can be increased when used in combination with Lacidipine.Approved, Investigational
LamotrigineThe therapeutic efficacy of Mevastatin can be increased when used in combination with Lamotrigine.Approved, Investigational
LansoprazoleThe serum concentration of Mevastatin can be increased when it is combined with Lansoprazole.Approved, Investigational
Lanthanum carbonateThe serum concentration of Mevastatin can be decreased when it is combined with Lanthanum carbonate.Approved
LapatinibThe serum concentration of Mevastatin can be increased when it is combined with Lapatinib.Approved, Investigational
LercanidipineThe serum concentration of Mevastatin can be increased when it is combined with Lercanidipine.Approved, Investigational
LevetiracetamThe therapeutic efficacy of Mevastatin can be increased when used in combination with Levetiracetam.Approved, Investigational
LevofloxacinThe serum concentration of Mevastatin can be increased when it is combined with Levofloxacin.Approved, Investigational
LevosalbutamolThe serum concentration of Mevastatin can be increased when it is combined with Levosalbutamol.Approved, Investigational
LidocaineThe serum concentration of Mevastatin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LidoflazineThe therapeutic efficacy of Mevastatin can be increased when used in combination with Lidoflazine.Experimental
LinagliptinThe serum concentration of Mevastatin can be increased when it is combined with Linagliptin.Approved
LipegfilgrastimMevastatin may increase the myelosuppressive activities of Lipegfilgrastim.Approved, Investigational
LomitapideThe serum concentration of Mevastatin can be increased when it is combined with Lomitapide.Approved, Investigational
LomustineThe serum concentration of Mevastatin can be increased when it is combined with Lomustine.Approved, Investigational
LoperamideThe therapeutic efficacy of Mevastatin can be increased when used in combination with Loperamide.Approved
LopinavirThe serum concentration of Mevastatin can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Mevastatin can be increased when it is combined with Loratadine.Approved, Investigational
Lorvotuzumab mertansineThe risk or severity of rhabdomyolysis can be increased when Lorvotuzumab mertansine is combined with Mevastatin.Investigational
LosartanThe metabolism of Losartan can be decreased when combined with Mevastatin.Approved
LovastatinThe serum concentration of Mevastatin can be increased when it is combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Mevastatin can be increased when it is combined with Luliconazole.Approved
LurasidoneThe serum concentration of Mevastatin can be increased when it is combined with Lurasidone.Approved, Investigational
MagaldrateThe serum concentration of Mevastatin can be decreased when it is combined with Magaldrate.Approved, Withdrawn
Magnesium carbonateThe serum concentration of Mevastatin can be decreased when it is combined with Magnesium carbonate.Approved, Investigational
Magnesium hydroxideThe serum concentration of Mevastatin can be decreased when it is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe serum concentration of Mevastatin can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Mevastatin can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium silicateThe serum concentration of Mevastatin can be decreased when it is combined with Magnesium silicate.Approved
Magnesium sulfateThe therapeutic efficacy of Mevastatin can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe serum concentration of Mevastatin can be decreased when it is combined with Magnesium Trisilicate.Approved
ManidipineThe serum concentration of Mevastatin can be increased when it is combined with Manidipine.Approved, Investigational
MefloquineThe serum concentration of Mevastatin can be increased when it is combined with Mefloquine.Approved, Investigational
MentholThe therapeutic efficacy of Mevastatin can be increased when used in combination with Menthol.Approved
MepartricinThe risk or severity of rhabdomyolysis can be increased when Mepartricin is combined with Mevastatin.Experimental
MequitazineThe serum concentration of Mevastatin can be increased when it is combined with Mequitazine.Approved
MethadoneThe serum concentration of Mevastatin can be increased when it is combined with Methadone.Approved
MethazolamideThe serum concentration of Mevastatin can be increased when it is combined with Methazolamide.Approved
MethimazoleThe serum concentration of Mevastatin can be increased when it is combined with Methimazole.Approved
MethsuximideThe therapeutic efficacy of Mevastatin can be increased when used in combination with Methsuximide.Approved
MethylergometrineThe serum concentration of Mevastatin can be increased when it is combined with Methylergometrine.Approved
MethylprednisoloneThe serum concentration of Mevastatin can be increased when it is combined with Methylprednisolone.Approved, Vet Approved
MetronidazoleThe serum concentration of Mevastatin can be increased when it is combined with Metronidazole.Approved
MetyraponeThe serum concentration of Mevastatin can be increased when it is combined with Metyrapone.Approved, Investigational
MibefradilThe serum concentration of Mevastatin can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Mevastatin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Mevastatin can be increased when it is combined with Midazolam.Approved, Illicit
MidecamycinThe risk or severity of rhabdomyolysis can be increased when Midecamycin is combined with Mevastatin.Approved
MifepristoneThe serum concentration of Mevastatin can be increased when it is combined with Mifepristone.Approved, Investigational
MiocamycinThe risk or severity of rhabdomyolysis can be increased when Miocamycin is combined with Mevastatin.Experimental
MirtazapineThe serum concentration of Mevastatin can be increased when it is combined with Mirtazapine.Approved
Mirvetuximab SoravtansineThe risk or severity of rhabdomyolysis can be increased when Mirvetuximab Soravtansine is combined with Mevastatin.Investigational
MitemcinalThe risk or severity of rhabdomyolysis can be increased when Mitemcinal is combined with Mevastatin.Investigational
MitoxantroneThe serum concentration of Mevastatin can be increased when it is combined with Mitoxantrone.Approved, Investigational
ModafinilThe serum concentration of Mevastatin can be increased when it is combined with Modafinil.Approved, Investigational
NabiloneThe serum concentration of Mevastatin can be increased when it is combined with Nabilone.Approved, Investigational
NaftopidilThe therapeutic efficacy of Mevastatin can be increased when used in combination with Naftopidil.Investigational
NatamycinThe risk or severity of rhabdomyolysis can be increased when Natamycin is combined with Mevastatin.Approved
NefazodoneThe serum concentration of Mevastatin can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Mevastatin can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Mevastatin can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Mevastatin can be increased when it is combined with Nevirapine.Approved
NiacinThe risk or severity of rhabdomyolysis can be increased when Niacin is combined with Mevastatin.Approved, Investigational, Nutraceutical
NicardipineThe serum concentration of Mevastatin can be increased when it is combined with Nicardipine.Approved, Investigational
NicotinamideThe serum concentration of Mevastatin can be increased when it is combined with Nicotinamide.Approved, Investigational
NifedipineThe serum concentration of Mevastatin can be increased when it is combined with Nifedipine.Approved
NiguldipineThe therapeutic efficacy of Mevastatin can be increased when used in combination with Niguldipine.Experimental
NilotinibThe serum concentration of Mevastatin can be increased when it is combined with Nilotinib.Approved, Investigational
NiludipineThe therapeutic efficacy of Mevastatin can be increased when used in combination with Niludipine.Experimental
NilvadipineThe serum concentration of Mevastatin can be increased when it is combined with Nilvadipine.Approved, Investigational
NimesulideThe therapeutic efficacy of Mevastatin can be increased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Mevastatin can be increased when used in combination with Nimodipine.Approved, Investigational
NisoldipineThe serum concentration of Mevastatin can be increased when it is combined with Nisoldipine.Approved
NitrendipineThe serum concentration of Mevastatin can be increased when it is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe serum concentration of Mevastatin can be increased when it is combined with Nitric Oxide.Approved
NorfloxacinThe serum concentration of Mevastatin can be increased when it is combined with Norfloxacin.Approved
NoscapineThe serum concentration of Mevastatin can be increased when it is combined with Noscapine.Investigational
NylidrinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Nylidrin.Approved
NystatinThe risk or severity of rhabdomyolysis can be increased when Nystatin is combined with Mevastatin.Approved, Vet Approved
OlanzapineThe serum concentration of Mevastatin can be increased when it is combined with Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Mevastatin can be increased when it is combined with Olaparib.Approved
OleandomycinThe risk or severity of rhabdomyolysis can be increased when Oleandomycin is combined with Mevastatin.Vet Approved
OmeprazoleThe serum concentration of Mevastatin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OtiloniumThe therapeutic efficacy of Mevastatin can be increased when used in combination with Otilonium.Experimental, Investigational
OxetacaineThe serum concentration of Mevastatin can be increased when it is combined with Oxetacaine.Approved, Investigational
OxybutyninThe serum concentration of Mevastatin can be increased when it is combined with Oxybutynin.Approved, Investigational
OxymetholoneThe serum concentration of Mevastatin can be increased when it is combined with Oxymetholone.Approved, Illicit
PaclitaxelThe serum concentration of Mevastatin can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Mevastatin can be increased when it is combined with Palbociclib.Approved, Investigational
ParamethasoneThe serum concentration of Mevastatin can be increased when it is combined with Paramethasone.Approved
PatupiloneThe risk or severity of rhabdomyolysis can be increased when Patupilone is combined with Mevastatin.Experimental, Investigational
PazopanibMevastatin may increase the hepatotoxic activities of Pazopanib.Approved
Peppermint oilThe serum concentration of Mevastatin can be increased when it is combined with Peppermint oil.Approved, Investigational
PergolideThe serum concentration of Mevastatin can be increased when it is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PhenelzineThe serum concentration of Mevastatin can be increased when it is combined with Phenelzine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Mevastatin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Mevastatin.Approved
PilocarpineThe serum concentration of Mevastatin can be increased when it is combined with Pilocarpine.Approved, Investigational
PimecrolimusThe risk or severity of rhabdomyolysis can be increased when Pimecrolimus is combined with Mevastatin.Approved, Investigational
PimozideThe serum concentration of Mevastatin can be increased when it is combined with Pimozide.Approved
PinaveriumThe therapeutic efficacy of Mevastatin can be increased when used in combination with Pinaverium.Approved
PiperaquineThe serum concentration of Mevastatin can be increased when it is combined with Piperaquine.Approved, Investigational
PosaconazoleThe serum concentration of Mevastatin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Mevastatin can be increased when it is combined with Pravastatin.Approved
PrednisoloneThe serum concentration of Mevastatin can be increased when it is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe serum concentration of Mevastatin can be increased when it is combined with Prednisone.Approved, Vet Approved
PrenylamineThe therapeutic efficacy of Mevastatin can be increased when used in combination with Prenylamine.Withdrawn
PrimaquineThe serum concentration of Mevastatin can be increased when it is combined with Primaquine.Approved
ProgesteroneThe absorption of Progesterone can be decreased when combined with Mevastatin.Approved, Vet Approved
PropofolThe serum concentration of Mevastatin can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Mevastatin.Approved, Investigational
QuinineThe serum concentration of Mevastatin can be increased when it is combined with Quinine.Approved
QuinupristinThe serum concentration of Mevastatin can be increased when it is combined with Quinupristin.Approved
RabeprazoleThe serum concentration of Mevastatin can be increased when it is combined with Rabeprazole.Approved, Investigational
RaloxifeneThe serum concentration of Mevastatin can be increased when it is combined with Raloxifene.Approved, Investigational
RaltegravirRaltegravir may increase the myopathic rhabdomyolysis activities of Mevastatin.Approved
RanitidineThe serum concentration of Mevastatin can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Mevastatin can be increased when it is combined with Ranolazine.Approved, Investigational
RegorafenibThe serum concentration of Mevastatin can be increased when it is combined with Regorafenib.Approved
RepaglinideThe serum concentration of Mevastatin can be increased when it is combined with Repaglinide.Approved, Investigational
ResveratrolThe serum concentration of Mevastatin can be increased when it is combined with Resveratrol.Approved, Experimental, Investigational
RidaforolimusThe risk or severity of rhabdomyolysis can be increased when Ridaforolimus is combined with Mevastatin.Investigational
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Mevastatin.Approved, Investigational
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Mevastatin.Approved
RifapentineThe serum concentration of Rifapentine can be increased when it is combined with Mevastatin.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Mevastatin.Approved, Investigational
RilpivirineThe serum concentration of Mevastatin can be increased when it is combined with Rilpivirine.Approved
RisperidoneThe serum concentration of Mevastatin can be increased when it is combined with Risperidone.Approved, Investigational
RitonavirThe serum concentration of Mevastatin can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe serum concentration of Mevastatin can be increased when it is combined with Rivastigmine.Approved, Investigational
RokitamycinThe risk or severity of rhabdomyolysis can be increased when Rokitamycin is combined with Mevastatin.Experimental
RolitetracyclineThe serum concentration of Mevastatin can be increased when it is combined with Rolitetracycline.Approved
RosuvastatinThe serum concentration of Mevastatin can be increased when it is combined with Rosuvastatin.Approved
RoxithromycinThe serum concentration of Mevastatin can be increased when it is combined with Roxithromycin.Approved, Investigational, Withdrawn
RucaparibThe serum concentration of Mevastatin can be increased when it is combined with Rucaparib.Approved, Investigational
RutinThe serum concentration of Mevastatin can be increased when it is combined with Rutin.Experimental, Investigational
SagopiloneThe risk or severity of rhabdomyolysis can be increased when Sagopilone is combined with Mevastatin.Investigational
SalbutamolThe serum concentration of Mevastatin can be increased when it is combined with Salbutamol.Approved, Vet Approved
SaquinavirThe serum concentration of Mevastatin can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe serum concentration of Mevastatin can be increased when it is combined with Sarilumab.Approved, Investigational
SelamectinThe risk or severity of rhabdomyolysis can be increased when Selamectin is combined with Mevastatin.Vet Approved
SeletracetamThe therapeutic efficacy of Mevastatin can be increased when used in combination with Seletracetam.Investigational
SertralineThe serum concentration of Mevastatin can be increased when it is combined with Sertraline.Approved
SildenafilThe serum concentration of Mevastatin can be increased when it is combined with Sildenafil.Approved, Investigational
SimeprevirThe serum concentration of Mevastatin can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Mevastatin can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Mevastatin can be increased when it is combined with Sirolimus.Approved, Investigational
SitaxentanThe serum concentration of Mevastatin can be increased when it is combined with Sitaxentan.Approved, Investigational, Withdrawn
Sodium bicarbonateThe serum concentration of Mevastatin can be decreased when it is combined with Sodium bicarbonate.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Mevastatin.Approved
SorafenibThe serum concentration of Mevastatin can be increased when it is combined with Sorafenib.Approved, Investigational
SpiramycinThe risk or severity of rhabdomyolysis can be increased when Spiramycin is combined with Mevastatin.Approved
St. John's WortThe metabolism of Mevastatin can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Mevastatin can be increased when it is combined with Stiripentol.Approved
SucralfateSucralfate can cause a decrease in the absorption of Mevastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SulfamethoxazoleThe serum concentration of Mevastatin can be increased when it is combined with Sulfamethoxazole.Approved
SulfanilamideThe serum concentration of Mevastatin can be increased when it is combined with Sulfanilamide.Approved
SulfinpyrazoneThe serum concentration of Mevastatin can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe serum concentration of Mevastatin can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Mevastatin.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Mevastatin.Approved, Investigational
TadalafilThe serum concentration of Mevastatin can be increased when it is combined with Tadalafil.Approved, Investigational
TamoxifenThe serum concentration of Mevastatin can be increased when it is combined with Tamoxifen.Approved
TelaprevirThe serum concentration of Mevastatin can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe risk or severity of rhabdomyolysis can be increased when Telithromycin is combined with Mevastatin.Approved
TemsirolimusThe serum concentration of Mevastatin can be increased when it is combined with Temsirolimus.Approved
TeniposideThe serum concentration of Mevastatin can be increased when it is combined with Teniposide.Approved
TerfenadineThe serum concentration of Mevastatin can be increased when it is combined with Terfenadine.Approved, Withdrawn
TerodilineThe therapeutic efficacy of Mevastatin can be increased when used in combination with Terodiline.Experimental
TesmilifeneThe serum concentration of Mevastatin can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Mevastatin can be increased when it is combined with Testosterone.Approved, Investigational
Testosterone cypionateThe serum concentration of Mevastatin can be increased when it is combined with Testosterone cypionate.Approved
Testosterone enanthateThe serum concentration of Mevastatin can be increased when it is combined with Testosterone enanthate.Approved
Testosterone undecanoateThe serum concentration of Mevastatin can be increased when it is combined with Testosterone undecanoate.Approved, Investigational
TetracyclineThe serum concentration of Mevastatin can be increased when it is combined with Tetracycline.Approved, Vet Approved
TetrahydropalmatineThe therapeutic efficacy of Mevastatin can be increased when used in combination with Tetrahydropalmatine.Investigational
ThiopentalThe serum concentration of Mevastatin can be increased when it is combined with Thiopental.Approved, Vet Approved
TicagrelorThe serum concentration of Mevastatin can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe serum concentration of Mevastatin can be increased when it is combined with Ticlopidine.Approved
TildipirosinThe risk or severity of rhabdomyolysis can be increased when Tildipirosin is combined with Mevastatin.Vet Approved
TilmicosinThe risk or severity of rhabdomyolysis can be increased when Tilmicosin is combined with Mevastatin.Investigational, Vet Approved
TioconazoleThe serum concentration of Mevastatin can be increased when it is combined with Tioconazole.Approved
TipranavirThe serum concentration of Mevastatin can be increased when it is combined with Tipranavir.Approved, Investigational
TofisopamThe serum concentration of Mevastatin can be increased when it is combined with Tofisopam.Approved
Tolfenamic AcidThe therapeutic efficacy of Mevastatin can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
TopiroxostatThe serum concentration of Mevastatin can be increased when it is combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Mevastatin can be increased when it is combined with Topotecan.Approved, Investigational
TrabectedinMevastatin may increase the myopathic rhabdomyolysis activities of Trabectedin.Approved, Investigational
TramadolThe serum concentration of Mevastatin can be increased when it is combined with Tramadol.Approved, Investigational
TranilastThe therapeutic efficacy of Mevastatin can be increased when used in combination with Tranilast.Approved, Investigational
TranylcypromineThe serum concentration of Mevastatin can be increased when it is combined with Tranylcypromine.Approved, Investigational
Trastuzumab emtansineThe risk or severity of rhabdomyolysis can be increased when Trastuzumab emtansine is combined with Mevastatin.Approved, Investigational
TrimebutineThe therapeutic efficacy of Mevastatin can be increased when used in combination with Trimebutine.Approved
TrimethadioneThe therapeutic efficacy of Mevastatin can be increased when used in combination with Trimethadione.Approved
TroglitazoneThe serum concentration of Mevastatin can be increased when it is combined with Troglitazone.Investigational, Withdrawn
TroleandomycinThe serum concentration of Mevastatin can be increased when it is combined with Troleandomycin.Approved
TromethamineThe serum concentration of Mevastatin can be decreased when it is combined with Tromethamine.Approved
TylosinThe risk or severity of rhabdomyolysis can be increased when Tylosin is combined with Mevastatin.Vet Approved
TylvalosinThe risk or severity of rhabdomyolysis can be increased when Tylvalosin is combined with Mevastatin.Vet Approved
Valproic AcidThe serum concentration of Mevastatin can be increased when it is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe serum concentration of Mevastatin can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Mevastatin can be increased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Mevastatin can be increased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Mevastatin can be increased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Mevastatin can be increased when it is combined with Vinorelbine.Approved, Investigational
VinpocetineThe therapeutic efficacy of Mevastatin can be increased when used in combination with Vinpocetine.Investigational
VoriconazoleThe serum concentration of Mevastatin can be increased when it is combined with Voriconazole.Approved, Investigational
WIN 55212-2The therapeutic efficacy of Mevastatin can be increased when used in combination with WIN 55212-2.Experimental
ZafirlukastThe serum concentration of Mevastatin can be increased when it is combined with Zafirlukast.Approved, Investigational
ZiconotideThe therapeutic efficacy of Mevastatin can be increased when used in combination with Ziconotide.Approved
ZiprasidoneThe serum concentration of Mevastatin can be increased when it is combined with Ziprasidone.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Mevastatin.Approved
ZonisamideThe therapeutic efficacy of Mevastatin can be increased when used in combination with Zonisamide.Approved, Investigational
ZucapsaicinThe serum concentration of Mevastatin can be increased when it is combined with Zucapsaicin.Approved, Investigational
Food Interactions
  • avoid alcohol
  • Grape fruit juice increases blood levels of the drug

References

Synthesis Reference

Scott Primrose, David King, Ed Yaworski, Jayaramaiyer Radhakrishnan, David He, Xinfa Xiao, "Fermentation process for preparation of compactin." U.S. Patent US5691173, issued September, 1977.

US5691173
General References
  1. Chemspider [Link]
  2. Pubchem [Link]
External Links
KEGG Compound
C13963
PubChem Compound
64715
PubChem Substance
99443247
ChemSpider
58262
BindingDB
50011036
ChEBI
34848
ChEMBL
CHEMBL54440
HET
2UO
Wikipedia
Mevastatin
PDB Entries
4oqr
MSDS
Download (350 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)152 °CPhysProp
logP3.95SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0321 mg/mLALOGPS
logP4.13ALOGPS
logP3.62ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)14.91ChemAxon
pKa (Strongest Basic)-2.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area72.83 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity108.63 m3·mol-1ChemAxon
Polarizability43.57 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9714
Blood Brain Barrier+0.639
Caco-2 permeable-0.6631
P-glycoprotein substrateSubstrate0.7964
P-glycoprotein inhibitor INon-inhibitor0.8324
P-glycoprotein inhibitor IIInhibitor0.6601
Renal organic cation transporterNon-inhibitor0.8617
CYP450 2C9 substrateNon-substrate0.8503
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.7206
CYP450 1A2 substrateNon-inhibitor0.8952
CYP450 2C9 inhibitorNon-inhibitor0.8909
CYP450 2D6 inhibitorNon-inhibitor0.8903
CYP450 2C19 inhibitorNon-inhibitor0.8513
CYP450 3A4 inhibitorInhibitor0.6571
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7992
Ames testNon AMES toxic0.8927
CarcinogenicityNon-carcinogens0.9523
BiodegradationNot ready biodegradable0.8854
Rat acute toxicity2.6058 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8359
hERG inhibition (predictor II)Non-inhibitor0.6699
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as delta valerolactones. These are cyclic organic compounds containing an oxan-2- one moiety.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Lactones
Sub Class
Delta valerolactones
Direct Parent
Delta valerolactones
Alternative Parents
Fatty acid esters / Oxanes / Dicarboxylic acids and derivatives / Secondary alcohols / Carboxylic acid esters / Oxacyclic compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Delta valerolactone / Fatty acid ester / Delta_valerolactone / Dicarboxylic acid or derivatives / Oxane / Fatty acyl / Carboxylic acid ester / Secondary alcohol / Carboxylic acid derivative / Oxacycle
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
carboxylic ester, delta-lactone, carbobicyclic compound, statin (naturally occurring) (CHEBI:34848)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Nadph binding
Specific Function
Transmembrane glycoprotein that is the rate-limiting enzyme in cholesterol biosynthesis as well as in the biosynthesis of nonsterol isoprenoids that are essential for normal cell function including...
Gene Name
HMGCR
Uniprot ID
P04035
Uniprot Name
3-hydroxy-3-methylglutaryl-coenzyme A reductase
Molecular Weight
97475.155 Da
References
  1. Kocarek TA, Dahn MS, Cai H, Strom SC, Mercer-Haines NA: Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes. Drug Metab Dispos. 2002 Dec;30(12):1400-5. [PubMed:12433810]
  2. Cenedella RJ, Kuszak JR, Al-Ghoul KJ, Qin S, Sexton PS: Discordant expression of the sterol pathway in lens underlies simvastatin-induced cataracts in Chbb: Thom rats. J Lipid Res. 2003 Jan;44(1):198-211. [PubMed:12518039]
  3. Stoebner PE, Michot C, Ligeron C, Durand L, Meynadier J, Meunier L: [Simvastatin-induced lichen planus pemphigoides]. Ann Dermatol Venereol. 2003 Feb;130(2 Pt 1):187-90. [PubMed:12671581]
  4. Pappu AS, Bacon SP, Illingworth DR: Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia. J Lab Clin Med. 2003 Apr;141(4):250-6. [PubMed:12677170]
  5. Liu L, Zhang R, Zhao JJ, Rogers JD, Hsieh JY, Fang W, Matuszewski BK, Dobrinska MR: Determination of simvastatin-derived HMG-CoA reductase inhibitors in biomatrices using an automated enzyme inhibition assay with radioactivity detection. J Pharm Biomed Anal. 2003 Apr 24;32(1):107-23. [PubMed:12852453]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Triglyceride lipase activity
Specific Function
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acy...
Gene Name
CES1
Uniprot ID
P23141
Uniprot Name
Liver carboxylesterase 1
Molecular Weight
62520.62 Da
References
  1. Fleming CD, Bencharit S, Edwards CC, Hyatt JL, Tsurkan L, Bai F, Fraga C, Morton CL, Howard-Williams EL, Potter PM, Redinbo MR: Structural insights into drug processing by human carboxylesterase 1: tamoxifen, mevastatin, and inhibition by benzil. J Mol Biol. 2005 Sep 9;352(1):165-77. [PubMed:16081098]

Drug created on March 13, 2010 15:07 / Updated on July 02, 2018 18:34